&nbsp;

Jun 2019

Drug

mercaptopurine

Other Name(s): Purinethol®

Quick Link(s):

Jun 2019

Drug

mitotane

Other Name(s): Lysodren®

Quick Link(s):

Jun 2019

Drug

midostaurin

Other Name(s): Rydapt®

Quick Link(s):

Jun 2025

Regimen

MELPPRED

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Drugs Used:

melphalan,

prednisone

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

MTRXVINO

Cancer Type:

Sarcoma,

Desmoid Tumour

Intent: Curative

Drugs Used:

methotrexate,

vinorelbine

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

MPT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Exceptional Access Program

thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

MFOLFOX6

Cancer Type:

Gynecologic,

Ovary

Intent: Adjuvant, Palliative

Drugs Used:

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

MIDO

Cancer Type:

Hematologic,

Rare Diseases

Intent: Palliative

Drugs Used:

midostaurin (Unfunded)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

MFOLFOX6+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

MFOLFIRINOX

Cancer Type:

Gastrointestinal,

Rectal

Intent: Neoadjuvant

Drugs Used:

Quick Link(s):

Regimen Monograph

Oct 2025

Regimen

MATRIX

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Drugs Used:

riTUXimab (Unfunded),

methotrexate,

cytarabine,

thiotepa (Unfunded)